09.09.15
Juliana M. Reed has been appointed vice president, Government Affairs at Coherus BioSciences, Inc., a global biosimilars company. Ms. Reed has more than 10 years in government affairs, specializing in global biosimilars policy.
"We welcome Juliana to the Coherus team," said Denny Lanfear, president and chief executive officer of Coherus. "Juliana is an accomplished executive who brings a wealth of experience, insight and leadership in the development of government policies that impact this new industry. The Coherus leadership team is composed of successful veterans who have helped pioneer the biologics industry. With the addition of Juliana, we now have one of the recognized leading experts on global biosimilar public policy. We look forward to working with Juliana in our efforts towards bringing affordable medications to patients and creating a vibrant marketplace for biosimilars in the US."
Ms. Reed has extensive experience in governmental and public affairs in the healthcare, pharmaceutical and medical device industries, including roles with Baxter and Hospira. She led the development and execution of the Hospira global biosimilars public policy strategy for the last 10 years, prior to the recent Pfizer acquisition of Hospira. She is the current president of the Biosimilars Forum, a not for profit group representing the U.S. biosimilars industry.
"We welcome Juliana to the Coherus team," said Denny Lanfear, president and chief executive officer of Coherus. "Juliana is an accomplished executive who brings a wealth of experience, insight and leadership in the development of government policies that impact this new industry. The Coherus leadership team is composed of successful veterans who have helped pioneer the biologics industry. With the addition of Juliana, we now have one of the recognized leading experts on global biosimilar public policy. We look forward to working with Juliana in our efforts towards bringing affordable medications to patients and creating a vibrant marketplace for biosimilars in the US."
Ms. Reed has extensive experience in governmental and public affairs in the healthcare, pharmaceutical and medical device industries, including roles with Baxter and Hospira. She led the development and execution of the Hospira global biosimilars public policy strategy for the last 10 years, prior to the recent Pfizer acquisition of Hospira. She is the current president of the Biosimilars Forum, a not for profit group representing the U.S. biosimilars industry.